• Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

  NCT06629363

  Not yet recruitingObservationalUpdated Jul 30, 2025
• Interrupters of VAscular daMAge in Malignant Hypertension

  NCT04991077

  CompletedObservationalUpdated Oct 30, 2024
• Mexican Registry of Pulmonary Hypertension

  NCT02252705

  CompletedObservationalUpdated Jun 28, 2023
• Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)

  NCT01038284

  CompletedInterventionalNot ApplicableUpdated Mar 17, 2014
• National Registry and Cohort Study of Pulmonary Vascular Disease

  NCT05368467

  RecruitingObservationalUpdated Jun 26, 2025
• Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics

  NCT01185730

  CompletedInterventionalNot ApplicableUpdated Apr 11, 2016

ClinicalTrials.gov ID

NCT03755726

Lead Sponsor

Centre Hospitalier de PAUOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

1,200Estimated

Last Update Posted

Mar 23, 2026Actual

Start Date

Sep 20, 2019Actual

Primary Completion Date

Sep 20, 2034Estimated

Completion Date

Sep 20, 2034Estimated

Official Title

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

Brief Summary

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Detailed Description

Malignant hypertension is the most severe form of high blood pressure, fatal if left untreated. It has not disappeared, with an increasing incidence. Patients with the disease, mainly young (35 to 55 years of age), have an unfavorable cardiovascular prognosis (14% of cardiovascular and renal events at 4 years). Despite these facts, scientific research on the subject remains limited. The definitions and diagnostic criteria have not changed since 1929, and the therapeutic recommendations remain empirical.

This first prospective and multicentric registry will increase and modernize the knowledge of the disease. From these data, diagnostic and therapeutic recommendations based on solid scientific evidence could be developed.

The investigators want to first recruit 500 patients and define their prognosis at 5 years. The impact of the patient's phenotype, type and number of target organs affected will be studied.

A modern definition, adapted to these results, could be proposed. The epidemiology of the disease, the care pathways, the target organ disorders and the management carried out in the centers will be described in detail.

• Malignant Hypertension

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy)
• Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure

Exclusion Criteria:

• Age < 18 years old
• Patients who cannot freely give their consent, or patients who refuse to participate
• Dialysis

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Centre Hospitalier de PAUOTHER

christophe.bachelet@me.com02 43 78 45 90

laurent.mesnard@aphp.fr01 56 01 65 02

romain.boulestreau@ch-pau.fr05 59 92 48 83